**Introduction**

Heterotopic ossification is progressive but self-limiting de novo trabecular bone formation occurring at skin, subcutaneous tissue, and skeletal muscle and periarticular tissues in which ossification doesn’t occur in normal conditions. This ectopic bone tissue, induced by osteoplastic activity, is an extra-articular bone localized to adjacent areas of joint and joint capsule is generally intact [1,2]. It involves large joints such as hip, elbow and knee (Figure 1). It generally appears 1-4 months after trauma, but it may also occur a few years after trauma. Clinic symptoms and signs become apparent at late phase [3-5]. HO is classified according to Broker’s Grading Scale scoring system in lower extremities and Hastings and Graham Grading Scale scoring system in upper extremities [6].

In general, trauma increases incidence of heterotopic ossification. Its incidence is 11-76% after head injury, 18-37% after spinal cord injury, 2-7% after total hip prosthesis, 1-3% after burns, and 0.5-1.2% after cerebrovascular events [7].

The diagnosis and management is of importance in HO which is frequently observed in orthopedic patients and those undergoing neurological rehabilitation. Treatment options include physical therapy to protect range of motion, drug therapy (etidronate, non-steroidal anti-inflammatory drugs), radiotherapy, and resection of ectopic bone tissue in joints with severe dysfunction [1,3,5,6].

Prophylaxis is more important than treatment in heterotopic ossification. Early mobilization is of importance in these patients. Risk factors should be eliminated in the development of heterotopic ossification. In addition, radiotherapy and NSAIDs have major role in the prophylaxis of heterotopic ossification [5-9].

The aim of this study was to assess etiology, clinical signs, and diagnostic and therapeutic options in patients received RT for heterotopic ossification.

**Figure 1:** Hyperdense lesions with varying sizes compatible with heterotopic ossification which are localized to soft tissue adjacent to knee joint on radiography.
Material and Method

Demographic characteristics of patients

We retrospectively reviewed patient files and/or electronic data of 12 patients who presented to Radiation Oncology Department of Kayseri Education and Research Hospital with HO and were treated between 2005 and 2013. Data regarding age, gender, history, etiology, radiological techniques, presenting complaints, drugs used, treatments received, treatment-related complications and follow-up times were extracted from patient records. Phone interviews with patients or their relatives were used in attempt to obtain missing data. The study was approved by Institutional Ethics Committee.

RT and medication

Two-dimensional treatment planning system using conventional X-ray simulator was used for planning radiotherapy. Planning target volume (PTV) was estimated to involve all sites of heterotopic ossification. Based on localization and extent of HO, radiotherapy was delivered with a total dose of 7 Gy (6-8 Gy) in a single fraction to areas (approximately 10x6 to 18x9 cm in size) from anterior-posterior parallel regions by linear accelerator devices (Linac) using 18 MV photon energies or Co-60. Indomethacin (75 mg/day over 15-20 days) was prescribed to all patients received postoperative RT.

Treatment response and follow-up

All patients were assessed on the months 1, 3 and 6 after completion of therapy. The assessment included physical examination, direct radiographs and/or arthritic MR imaging or CT scan. Radiological assessments were performed according to ossification degree (0-4 points) by using Broker’s Grading Scale for lower extremities and Hastings and Graham Grading Scale for upper extremities. Unresponsiveness was defined as increased ossification scores in radiological assessment after completion of radiotherapy. Clinical information was obtained through phone interviews in patients not attending to follow-up visits.

Results

Table 1 presents demographic characteristics of patients. Of 12 patients presented and were treated for HO, 8 were men. Median age was 44.4 years (range: 20-72). There was hypertension, diabetes mellitus and coxarthrosis in the history of patients. It was seen that most common triggers are traffic accident and fracture for HO. HO incidence was highest in hip joint (n=7), followed by elbow (n=3) and knee joints (n=2). Perioperative radiotherapy was given in 7 patients, whereas it was given to prevent HO in 5 patients. The most common HO-related complaints were pain and limitation of movement. Based on Hastings and Graham classification, there was grade IIA (n=1), IIC (n=1), and I (n=1) ossification among elbow joints. Based on Broker’s classification, there was grade I (n=3) and II (n=6) ossification among hip joints.

Table 2 presents parameters of RT given. RT was delivered with a total dose of 7 Gy (6-8 Gy) in a single fraction to areas (approximately 10x6 to 18x9 cm in size) from anterior-posterior parallel regions by using Co-60 or 18 MV photon devices. Mean time from surgery to RT was 24 hours in 6 patients and 48 hours in one patient. Indomethacin (75 mg per day, divided in 3 doses, over 15-20 days) was prescribed to patients received postoperative RT. No acute or subacute complication was observed. RT wasn’t repeated in any patient.

Median follow-up was 25.3 months (range: 2-69). Two patients didn’t attend to control visit on the months 3 and 6. Outcomes were assessed according to physical examination and radiological evaluations. There was no increase in Broker’s ossification score in patients received postoperative radiotherapy. One patient who received postoperative radiotherapy but didn’t attend to control visits was interviewed by phone. It was seen that radiotherapy was effective by 100% based on clinical prophylaxis. Of the patients received prophylactic radiotherapy for elbow joint, it was seen that there was no increase in radiological Hastings and Graham ossification scores in 2 patients. In this group, it was seen that radiotherapy was effective by 60% in one patient who didn’t attend to control visits.
Discussions

Heterotopic ossification was first described with its clinical, patho-anatomic and radiological characteristics in patients with traumatic paraplegia (paraosteoarthropathy) by Dejerine and Ceullier in 19th century. In the literature, de novo periarticular bone formation is denoted with several terms including myositis ossificans, paraosteoarthropathy, neurogenic ossifying fibromopathy [1,5,7,10,11].

Although HO has been known for over a hundred year, there is an ongoing debate regarding etiology, pathogenesis and management [8,12,13]. It is understood that there is a need for further studies on patients at risk for HO or with HO in order to create a health policy.

Pathophysiology of heterotopic ossification isn’t fully elucidated. It is suggested that HO may result from metaplastic response of mesenchymal cells induced by interaction between systemic factors and local, metabolic, vascular, genetic and biochemical factors [3,7]. Immobilization, pressure ulcers, trauma, fracture, dislocation, burn, infection, hemotoma and several neurological disorders are implied in the etiology [1,2,5,14]. Swelling, effusion, erythema and warmth as well as pain appear 2 weeks after trauma. Localized mass, pain and limitation of movement are typical in the course of disease. These clinical symptoms are seen within 8-10 weeks [3,7]. Laboratory and radiology studies will be helpful in diagnosis. Direct radiographies are invaluable in the diagnostic process, as HO become visible on radiology studies will be helpful in diagnosis. Direct radiographies after 1-2 months, where maturation occurs. Computerized tomography can reveal both HO localization and its relationship with adjacent tissues as well as it is valuable as a guide for treatment [2,6]. Traffic accident (spasticity, prolonged coma, immobilization) and hip fractures were primary risk factors in our study. It was most frequently observed at hip joint; followed by elbow. The most common complaints were pain and limitation of movements. Direct radiographies and MR imaging/CT scans were used in diagnosis and follow-up. Our findings were consistent with literature.

In our study, RT was applied to 12 patients in order to prevent HO. By the idea that it could be more effective in patients underwent total hip arthroplasty, combined therapy (RT plus NSAID) was prescribed on the postoperative day 1. In patients with HO at elbow, there was persistent clinical progression and complaints including pain and limitation that caused marked decrease in quality of life despite physical therapy and drug use. RT was indicated due to refractory disease in these patients. In most patients, RT was delivered with 7 Gy in single fraction, taking recent studies on treatment protocol into consideration. In our study, no radiological recurrence of heterotopic ossification was observed in any patient received postoperative RT after 25 months follow-up. In patient received RT to elbow joint, no increase was observed in HO in radiological follow-up. HO is generally seen large joints. It is more frequently seen at hip, knee, shoulder and elbow joints [1,12]. HO formation is most rapid within first 1-4 months. Thus, it is important to initiate management as soon as possible after diagnosis. Radiotherapy and NSAIDs have a major role in heterotopic ossification prophylaxis [8,13-16].

NSAIDs, indomethacin in particular, prevent transformation of mesenchymal cells to osteogenic cells that generate bone tissue. Although NSAIDs are widely used, they are associated with adverse effects such as gastrointestinal disorders or compliance issues [8,10]. RT is another method used in prophylaxis. Radiotherapy prevents HO formation by inhibiting mesenchymal cell development which is thought to be progenitor in ossification. Moreover, low dose radiotherapy also has anti-inflammatory activity [9,11,16]. In previous studies, HO incidence after total hip replacement was reported as 8-90%, while it was reported as 35-57% in large series [7,8,13,17]. In a meta-analysis including 7 studies on 1143 patients, Pakos et al., compared radiotherapy to anti-inflammatory drugs regarding efficiency in preventing HO. Authors concluded that postoperative radiotherapy at appropriate doses was more effective than anti-inflammatory drugs [8]. In a meta-analysis by Baird et al., HO incidence was evaluated in patients undergoing total hip arthroplasty. Authors reported HO incidence as 58% in patients underwent surgery alone, 37% in patients received indomethacin alone, 27% in patients received radiotherapy alone and 12% in those received RT plus indomethacin [1]. In the studies by Balboni et al. and Maurad et al., it was suggested that postoperative single dose radiotherapy (8Gy) in combination with indomethacin should be given to prevent recurrence in patients at high risk [3,12].

There are several studies regarding timing, dose and route of radiotherapy in the literature. It has been shown that radiotherapy is more effective in the early phase of HO. It is recommended that surgery alone increases recurrence rates and radiotherapy should

---

Table 2: Treatment characteristics and follow-up durations.

<table>
<thead>
<tr>
<th>Patients</th>
<th>RT location</th>
<th>HO score</th>
<th>RT device</th>
<th>RT dose</th>
<th>Filed size</th>
<th>Preop</th>
<th>Postop</th>
<th>Combination therapy</th>
<th>Complication of RT</th>
<th>Irradiation</th>
<th>Follow up +/-</th>
<th>Follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>elbow</td>
<td>IIA</td>
<td>Co-60</td>
<td>7</td>
<td>14x7</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>hip</td>
<td>II</td>
<td>Co-60</td>
<td>8</td>
<td>16x9</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9</td>
</tr>
<tr>
<td>3</td>
<td>elbow</td>
<td>IIC</td>
<td>Co-60</td>
<td>6</td>
<td>11x8</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>elbow</td>
<td>II</td>
<td>Co-60</td>
<td>8</td>
<td>10x12</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>60</td>
</tr>
<tr>
<td>5</td>
<td>hip</td>
<td>II</td>
<td>Co-60</td>
<td>7</td>
<td>13.4x11</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>knee</td>
<td>II</td>
<td>Co-60</td>
<td>7</td>
<td>16x17</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>22</td>
</tr>
<tr>
<td>7</td>
<td>hip</td>
<td>I</td>
<td>Co-60</td>
<td>7</td>
<td>11x18</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>11</td>
</tr>
<tr>
<td>8</td>
<td>hip</td>
<td>I</td>
<td>Co-60</td>
<td>7</td>
<td>14x20</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>27</td>
</tr>
<tr>
<td>9</td>
<td>hip</td>
<td>II</td>
<td>Co-60</td>
<td>6</td>
<td>13x10</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>12</td>
</tr>
<tr>
<td>10</td>
<td>knee</td>
<td>II</td>
<td>Co-60</td>
<td>7</td>
<td>10x6</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>69</td>
</tr>
<tr>
<td>11</td>
<td>hip</td>
<td>II</td>
<td>Linac</td>
<td>7</td>
<td>14x14</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>65</td>
</tr>
<tr>
<td>12</td>
<td>hip</td>
<td>I</td>
<td>Linac</td>
<td>7</td>
<td>15x16</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>12</td>
</tr>
</tbody>
</table>

be given at preoperative and early postoperative period to prevent recurrence. It is recommended that radiotherapy should be given within first 72 hours after surgery or 1, 2, 4, 16 or 29 hours prior to surgery [12,15,16,18,19]. In a study Kantorowitz et al., a significant difference was found between applications of radiotherapy (7 Gy) 4 hours before surgery and radiotherapy (7 Gy) applied within first 72 hours after surgery regarding HO prevention. Authors reported that preoperative radiotherapy was more effective [16,20]. In a study on patients undergoing total hip arthroplasty by DeFlitch et al., radiotherapy was given within first 72 hours to 75% of patients to prevent HO and authors reported that HO developed in 55% of these patients [5]. In the studies by Rumi et al. and Seegen et al., it was reported that both preoperative and postoperative radiotherapy prevented HO by 85–95% in patients at high risk for HO development [13,19].

It is recommended to apply early postoperative radiotherapy at fractionated doses (total dose of 10 Gy) or at a dose of 6-8 Gy at single fraction in order to prevent recurrence after surgery. Previous studies demonstrated that there was no difference between single dose and fractionated doses [9,14,15,17,21,22]. However, single dose radiotherapy is more widely preferred due to its ease application. In a study by Hedley et al., single dose radiotherapy (6 Gy) was shown to be effective in 17 patients underwent hip arthroplasty. This finding indicated that minimum effective dose was 6 Gy in preventing HO development [21]. In a study, Healy et al. compared single doses with 5.5 Gy and 7 Gy in preventing HO. In that study, HO formation was observed in 63% of the patients received single dose radiotherapy with 5.5 Gy, while, it was observed in only 10% of the patient received single dose radiotherapy with 7 Gy [9]. In another study, perioperative radiotherapy was given to 9 patients who underwent surgical resection for heterotopic ossification that was already present at elbow. Radiotherapy was delivered with a total dose of 1000 Rad in 2 fractions in 5 patients, whereas remaining 4 patients received a single dose radiotherapy with 600 Rad. After mean follow-up 7 months, no radiological recurrence of heterotopic ossification was observed in any of the patients, and authors suggested that prophylactic radiotherapy was effective [14].

In conclusion, radiotherapy in combination with anti-inflammatory drugs is an effective treatment algorithm in patients at high-risk for HO development such as those undergoing total hip replacement. However, there is a need for further clinical trials with larger sample size that assess effectiveness and adverse effects of prophylactic RT in HO according to age groups.

References